Skip to main content
    C

    Corvus Pharmaceuticals Inc (CRVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.17
    -0.43 (-4.06%)

    Market Cap: $897.52M

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Corvus Pharmaceuticals Inc (CRVS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Corvus Pharmaceuticals (CRVS) has a market cap of $897.52M and an enterprise value of $882.50M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 11.65% from a year earlier.

    Total Valuation

    Enterprise value is 1.67% below the market cap, as cash exceeds debt.

    Market Cap$897.52M
    Enterprise Value$882.50M
    Latest price (Nov 17, 2026)$10.17

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.13% in the quarter ended Sep 30, 2026 and grew 17.75% a year over 2 years.

    Shares Outstanding92.49M
    Shares Change (YoY)+11.65%
    Shares Change (QoQ)+0.13%
    Share Count Growth (2Y CAGR)+17.75%

    Price Statistics

    The stock is up 15.96% over 52 weeks and trades 7.80% below its 50-day average.

    Beta (1Y)0.67
    52-Week Change+15.96%
    1-Month Change+5.39%
    3-Month Change-33.96%
    6-Month Change-11.57%
    5-Year Change+121.41%
    10-Year Change-24.87%
    Total Return (1Y)+15.96%
    Total Return (3Y CAGR)+91.39%
    Total Return (5Y CAGR)+24.37%
    Return vs SPY (1Y)+0.32%
    Max Drawdown (1Y)-63.24%
    Max Drawdown (3Y)-70.50%
    Sharpe Ratio (1Y)0.10
    Correlation with SPY (1Y)0.08
    50-Day Average$11.03
    200-Day Average$13.89
    52-Week Range$6.39 to $26.95
    RSI (14 Days)44.5
    Average Volume (20 Days)986.39K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 13.38x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio13.38x
    Quick Ratio13.38x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -30.87% over the last 12 months, against a 5-year average of -80.85%.

    Return on Equity (ROE)-30.87%
    Return on Assets (ROA)-28.73%
    ROE (5Y Average)-80.85%
    ROA (5Y Average)-54.25%
    ROIC (5Y Average)-20.43%

    Scores

    CRVS has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$26.00K
    Operating Income-$67.75M
    Pretax Income-$61.41M
    Net Income-$64.31M
    Reported EPS (TTM)-$0.71

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 93.05% of the $223.88M in total assets.

    Cash and Equivalents$15.01M
    Total Debt$0
    Net Cash$15.01M
    Net Cash Per Share$0.16
    Working Capital$190.93M
    Shareholder Equity$208.32M
    Book Value Per Share$2.25
    Total Assets$223.88M
    Total Liabilities$15.56M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $764.00K of capital spending, operating cash flow left -$47.94M of free cash flow.

    Operating Cash Flow-$47.18M
    Capital Expenditures$764.00K
    Free Cash Flow-$47.94M
    FCF Per Share-$0.57
    Depreciation and Amortization$905.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-1.36%
    Tangible Book Per Share Growth (2Y CAGR)-1.36%

    Revenue and profit by year

    Dividends and Yields

    CRVS does not pay a dividend. Its free cash flow yield is -5.10%.

    FCF Yield-5.10%
    Buyback Yield-20.14%
    Shareholder Yield-20.14%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CRVS

    What is CRVS's market cap?

    Corvus Pharmaceuticals has a market cap of $897.52M. Its enterprise value, which adds debt and subtracts cash, is $882.50M.

    How many shares of CRVS are outstanding?

    Corvus Pharmaceuticals has 92.49M shares outstanding. The count is up 11.65% from a year earlier.

    Does CRVS pay a dividend?

    No. Corvus Pharmaceuticals does not pay a dividend.

    How much debt does CRVS have?

    Corvus Pharmaceuticals has $0 of total debt and $15.01M of cash and equivalents, a net cash position of $15.01M.